(Total Views: 440)
Posted On: 09/22/2024 9:40:48 PM
Post# of 148863
MDNA11 is a Long-acting “Beta-enhanced Not-alpha” IL-2
Distinctive Features of MDNA11
➢ Highly Selective Anti-tumor Effector Immune Cell Activation:
o “Beta-enhanced” IL-2 agonist promoting selective activation of CD8+ T and NK cells
o “Not-alpha” binding with negligible to no expansion of Tregs
➢ Improved Safety Profile Over High-dose rhIL-2: No vascular leak syndrome or significant eosinophilia
➢ Extended PK: Albumin fusion prolongs half-life (given IV Q2W)
➢ Tumor Accumulation: Albumin promotes retention in tumor and tumor-draining lymph nodes
MDNA11
IL-2 Component
IL-2 component of MDNA11 is
engineered to increase IL2Rβ affinity and
eliminate IL2R???? binding
(G4S)3 linker
Human Albumin
Fusion to human albumin extends half
life, overcoming need for frequent dosing
and promotes MDNA11 accumulation in
tumors
https://ir.medicenna.com/static-files/6c3ac05...284fa6fcd4
Distinctive Features of MDNA11
➢ Highly Selective Anti-tumor Effector Immune Cell Activation:
o “Beta-enhanced” IL-2 agonist promoting selective activation of CD8+ T and NK cells
o “Not-alpha” binding with negligible to no expansion of Tregs
➢ Improved Safety Profile Over High-dose rhIL-2: No vascular leak syndrome or significant eosinophilia
➢ Extended PK: Albumin fusion prolongs half-life (given IV Q2W)
➢ Tumor Accumulation: Albumin promotes retention in tumor and tumor-draining lymph nodes
MDNA11
IL-2 Component
IL-2 component of MDNA11 is
engineered to increase IL2Rβ affinity and
eliminate IL2R???? binding
(G4S)3 linker
Human Albumin
Fusion to human albumin extends half
life, overcoming need for frequent dosing
and promotes MDNA11 accumulation in
tumors
https://ir.medicenna.com/static-files/6c3ac05...284fa6fcd4
(3)
(0)Scroll down for more posts ▼
